HOME > COLUMN

COLUMN

Maurer’s Healthcare Insight (140)

December 26, 2011
Maurer’s Healthcare Insight (139)

December 12, 2011
Maurer’s Healthcare Insight (138)

November 21, 2011
Maurer’s Healthcare Insight（137）

October 17, 2011
Maurer’s Healthcare Insight (136)

September 12, 2011
Maurer's Healthcare Insight (135)

August 15, 2011
Maurer's Healthcare Insight (134)

August 1, 2011
Maurer's Healthcare Insight (133)

July 11, 2011
Maurer's Healthcare Insight (132)

May 30, 2011
Maurer's Healthcare Insight (131)

April 18, 2011
Maurer's Healthcare Insight (130)

January 24, 2011
Maurer's Healthcare Insight (129)

January 3, 2011
Maurer's Healthcare Insight (128)

December 13, 2010
Maurer's Healthcare Insight (127)

November 29, 2010
Maurer's Healthcare Insight (126)

November 8, 2010
Maurer's Healthcare Insight (125)

October 25, 2010
Maurer's Healthcare Insight (124)

October 11, 2010
Maurer's Healthcare Insight (123)

July 12, 2010
Maurer's Healthcare Insight (122)

May 31, 2010
Maurer's Healthcare Insight (121)

May 3, 2010

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…